Qiagen

The PCR test detects HIV-1 RNA on the NeuMoDx 96/288 Molecular Systems and joins the company's other bloodborne viral tests for hepatitis B and C.

Private equity firms KKR and Ampersand Capital have reportedly proposed acquiring Oxford Immunotec for around $15 per share in cash.

News items for the in vitro diagnostics industry for the week of May 25, 2020.

The firm said it can produce enough viral RNA extraction reagents to support more than 7 million real-time PCR tests per month for detecting SARS-CoV-2.

The company had announced on March 3 that the lenders had committed to the debt financing in connection with its proposed acquisition of Qiagen.

The PCR-based tests, which detect SARS-CoV-2 nucleic acid, are limited to use in the labs where they were developed, according to the FDA.

Preliminary Q1 revenues and EPS benefitted from product sales for COVID-19 testing and significantly exceeded previously issued guidance.

The NeuMoDx SARS-CoV-2 Test Strip can run on the firm's fully-automated mid- or high-throughput instruments.

The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.